Gene Therapy Cuts Canavan Disease Symptoms in Kids
Executive Brief
- The News: Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease
- Clinical Win: Preliminary efficacy data from raw datasets generated in this study
- Target Specialty: Pediatric neurologists managing Canavan disease in children
Key Data at a Glance
Disease: Canavan disease
Study Phase: Phase 1/2 trial
Population: Children
Funding Source: Myrtelle, Inc.
Regulatory Agency: FDA
Therapy Type: Adeno-associated virus gene therapy
Gene Therapy Cuts Canavan Disease Symptoms in Kids
At the outset of the trial, we omitted a data-sharing provision from the consent documents signed by participants. As a result, in accordance with our Ethics Committee policies, we are not authorized to release the raw data to the public. Furthermore, the study is still in progress. De-identified patient characteristics, safety and preliminary efficacy data from raw datasets generated in this study are included in the paper. Requests for more information about the raw data are subject to a confidentiality agreement with Myrtelle and must comply with applicable legal and regulatory requirements. Qualified researchers may request access to the trial information by contacting corresponding author O.F. The requests will be addressed within 120 days, and data transfer agreement may be required.
We thank the patients and families who generously contributed their time, courage and commitment to this research that made this study possible. We also wish to thank all of the Canavan Disease Patient Advocacy Groups worldwide for their commitment to research and patient care in this community, and the entire team at Dayton Children's Hospital for their support and collaboration. We sincerely thank S. Hesterlee, now interim president and CEO of the Muscular Dystrophy Association, for her exceptional guidance and support during the early development of this program in her former role as program director of the Canavan Disease Program. We also thank L. E. Kratz and the Kennedy Krieger Institute Biochemical Genetics Lab for analyzing the CSF NAA samples. We thank A. Pace for statistical support on this project, particularly with MSEL statistical analysis. We also wish to acknowledge the important scientific contributions of J. R. Samulski and S. Gray, whose expertise has been instrumental during the first phase of this program. We gratefully acknowledge the members of the Independent Data Monitoring Committee for their expert guidance, oversight and commitment to ensuring the integrity of the trial. Their independent review and thoughtful recommendations have been invaluable in guiding the conduct of this study. We thank the FDA for their supportive guidance and for recognizing the urgent, unmet needs of patients and families affected by this devastating disease and their commitment to accelerating the progress of this program. This study is funded by Myrtelle, Inc. Paper preparation support, provided by J. G. Jacobson, InSeption Group, was also funded by Myrtelle, Inc.
These authors contributed equally: Paola Leone, Robert M. Lober.
Authors and Affiliations
Rowan-Virtua Health College of Medicine and Life Sciences, Rowan-Virtua SOM and Translational Biomedical Engineering and Sciences, Stratford, NJ, USA
Paola Leone, Jeremy Francis & Christopher G. Janson
Wright State-Premier Health Neuroscience Institute, Dayton, OH, USA
Robert M. Lober & Christopher G. Janson
Division of Neurosurgery, Dayton Children’s Hospital, Dayton, OH, USA
Robert M. Lober & Christopher G. Janson
Myrtelle, Inc., New York, NY, USA
Olga Flamini & David Shera
Departments of Radiology, Pediatrics, Neuroscience, Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Christopher G. Janson
P.L. contributed to study design, data interpretation, revision of the paper and approval of the paper for submission. R.M.L. contributed to data interpretation, revision of the paper and approval of the paper for submission. J.F. contributed to data interpretation, revision of the paper and approval of the paper for submission. O.F. contributed to data interpretation, writing and revision of the paper and approval of the paper for submission. C.G.J. contributed to data analysis and interpretation, writing and revision of the paper, approval of the paper for submission. D.S. contributed to statistical analyses, revision of the paper and approval of the paper for submission. K.M.C. contributed to data interpretation, revision of the paper and approval of the paper for submission.
Corresponding authors
Correspondence to Olga Flamini or Christopher G. Janson.
Clinical Perspective — Dr. Priya Kapoor, Obstetrics and Gynecology
Workflow: As I consider gene therapy for Canavan disease, I'd need to adjust my workflow to accommodate the unique requirements of this treatment, such as CSF NAA sample analysis. The involvement of specialized labs, like the Kennedy Krieger Institute Biochemical Genetics Lab, means I'd need to coordinate with external teams. This collaboration would likely add a few extra steps to my routine.
Economics: The article doesn't address cost directly, but it does mention that the study is funded by Myrtelle, Inc. This suggests that the company is invested in bringing this gene therapy to market, which could potentially impact the cost of treatment in the future. However, without specific numbers, it's difficult to say how this will affect my patients' access to care.
Patient Outcomes: While the article doesn't provide explicit outcome data, it does highlight the importance of addressing the "urgent, unmet needs of patients and families affected by" Canavan disease. As a doctor, I'm eager to see how oligodendrocyte-targeted adeno-associated virus gene therapy can improve the lives of my patients with this devastating disease, and I'll be watching for future updates on the trial's progress.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].